Frazier Life Sciences Management, L.P.
CIK 0001892134 · PALO ALTO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$4.59B
2026 Q2
Positions
41
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
73.6%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
MIRM
MIRUM PHARMACEUTICALS INC
19.6%
NAMS
NEWAMSTERDAM PHARMA COMPANY
13.3%
ERAS
ERASCA INC
10.0%
MBX
MBX BIOSCIENCES INC
8.0%
ARQT
ARCUTIS BIOTHERAPEUTICS INC
5.6%
TRVI
TREVI THERAPEUTICS INC
4.0%
KRYS
KRYSTAL BIOTECH INC
3.9%
MAZE
MAZE THERAPEUTICS INC
3.3%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.